Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases
Multitarget drugs are molecules with the ability to act simultaneously on different targets at the same time, and they have been evaluated in the last decade as a powerful tool in the development of promising therapeutics for neurodegenerative diseases. This is very useful for multifactorial disease...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/6/831 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849431765676982272 |
|---|---|
| author | Eleftheria-Emmanouela Katsoulaki Dimitrios Dimopoulos Dimitra Hadjipavlou-Litina |
| author_facet | Eleftheria-Emmanouela Katsoulaki Dimitrios Dimopoulos Dimitra Hadjipavlou-Litina |
| author_sort | Eleftheria-Emmanouela Katsoulaki |
| collection | DOAJ |
| description | Multitarget drugs are molecules with the ability to act simultaneously on different targets at the same time, and they have been evaluated in the last decade as a powerful tool in the development of promising therapeutics for neurodegenerative diseases. This is very useful for multifactorial diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases, a group of neurological disorders that induce neurodegeneration and neuroinflammation. Successful drug design for multifactorial diseases depends on an interdisciplinary and collaborative approach. The complexity of the above pathologies has clearly demonstrated that such single-target drugs are inadequate to achieve a successful therapeutic result. Furthermore, molecules hitting more than one biological target exhibit also a safer profile. In this review, we present a comprehensive knowledge of recent research on multitarget synthetic approaches to confront Alzheimer’s, Parkinson’s, and Huntington’s neurodegenerative diseases. |
| format | Article |
| id | doaj-art-61a4efcd3c044d769526ab9a32e0fdf5 |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-61a4efcd3c044d769526ab9a32e0fdf52025-08-20T03:27:32ZengMDPI AGPharmaceuticals1424-82472025-06-0118683110.3390/ph18060831Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration DiseasesEleftheria-Emmanouela Katsoulaki0Dimitrios Dimopoulos1Dimitra Hadjipavlou-Litina2Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, GreeceLaboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, GreeceLaboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, GreeceMultitarget drugs are molecules with the ability to act simultaneously on different targets at the same time, and they have been evaluated in the last decade as a powerful tool in the development of promising therapeutics for neurodegenerative diseases. This is very useful for multifactorial diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases, a group of neurological disorders that induce neurodegeneration and neuroinflammation. Successful drug design for multifactorial diseases depends on an interdisciplinary and collaborative approach. The complexity of the above pathologies has clearly demonstrated that such single-target drugs are inadequate to achieve a successful therapeutic result. Furthermore, molecules hitting more than one biological target exhibit also a safer profile. In this review, we present a comprehensive knowledge of recent research on multitarget synthetic approaches to confront Alzheimer’s, Parkinson’s, and Huntington’s neurodegenerative diseases.https://www.mdpi.com/1424-8247/18/6/831Alzheimer’s diseaseParkinson’s diseaseHuntington’s diseaseneurodegenerative diseasesmultitarget drugshybrid compounds |
| spellingShingle | Eleftheria-Emmanouela Katsoulaki Dimitrios Dimopoulos Dimitra Hadjipavlou-Litina Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases Pharmaceuticals Alzheimer’s disease Parkinson’s disease Huntington’s disease neurodegenerative diseases multitarget drugs hybrid compounds |
| title | Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases |
| title_full | Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases |
| title_fullStr | Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases |
| title_full_unstemmed | Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases |
| title_short | Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases |
| title_sort | multitarget compounds designed for alzheimer parkinson and huntington neurodegeneration diseases |
| topic | Alzheimer’s disease Parkinson’s disease Huntington’s disease neurodegenerative diseases multitarget drugs hybrid compounds |
| url | https://www.mdpi.com/1424-8247/18/6/831 |
| work_keys_str_mv | AT eleftheriaemmanouelakatsoulaki multitargetcompoundsdesignedforalzheimerparkinsonandhuntingtonneurodegenerationdiseases AT dimitriosdimopoulos multitargetcompoundsdesignedforalzheimerparkinsonandhuntingtonneurodegenerationdiseases AT dimitrahadjipavloulitina multitargetcompoundsdesignedforalzheimerparkinsonandhuntingtonneurodegenerationdiseases |